Erleada Market Size, Forecast, and Drug Insight – 2030 Erleada (apalutamide), developed by Janssen Pharmaceuticals, has become a leading therapeutic option in the treatment of prostate cancer. As a non-steroidal anti-androgen, Erleada works by inhibiting androgen receptors, which are critical for the growth and progression of prostate cancer cells. This article explores the market size, forecast, and emerging drug insights for Erleada through 2030. For More : https://www.delveinsight.com/sample-request/erleada-drug-insight-and-market-forecast